Travoprost monotherapy effective for POAG

Article

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

In a 5-year study reported in the Journal of Glaucoma, 36 previously untreated POAG patients received topical travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories), once in the evening in both eyes.

All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.

In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:

  • 16.8 (±2.4) mmHg at the 1-year assessment, a 28.4% decrease in IOP from baseline.
  • 16.8 (±2.5) mmHg at the 2-year assessment (-28.1% from baseline)
  • 16.8 (±2.4) mmHg at the 3-year assessment (-28.5% from baseline)

  • 16.7 (±2.5) mmHg at the 4-year assessment (-28.6% from baseline)
  • 16.9 (±2.4) mmHg at the 5-year assessment (-27.8% from baseline)

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.